Drugs / GT-002
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03817346 Comparator | Dec 2018 → Mar 2019 | — | Gabather AB | Completed | No outcome recorded |
Press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03817346 ↗ |
| Route | Oral | “The study drug (GT-002 or placebo) will be administered orally as a single dose.” NCT03817346 ↗ |